Kornimate/medical-research-clean huggingface dataset:
a quality of life study of peginterferon-alfa-2a plus ribavirin in participants with chronic hepatitis c and persistently normal alanine transaminase (alt) levels

Conditions: Hepatitis C, Chronic

Summary: participants with chronic hepatitis c (chc) and normal alt, who have been under treatment with peginterferon alfa-2a and ribavirin for at least 4 weeks, will be enrolled into this non-interventional, open-label study. the primary aim is to evaluate quality of life according to the 36-item short-form health survey (sf-36) questionnaire, modified for the greek population.


Eligibility criteria:
inclusion criteria: * serological confirmation of chronic infection by anti-hepatitis c virus (hcv) assay * hcv ribonucleic acid (rna) positive * chc with normal transaminases * compensated liver disease * non-pregnant and willing to use two contraceptive methods (if fertile) * at least 4 weeks of prior treatment with peginterferon alfa-2a and ribavirin exclusion criteria: * pregnant or lactating women * co-infection with hepatitis a or b, or human immunodeficiency virus (hiv) * history of seizures or depression * history of autoimmune disease, severe heart or lung disease, or renal failure with reduced creatinine clearance * uncontrolled thyroid disease * severe retinopathy * leukopenia or thrombocytopenia * bleeding esophageal varices or other evidence of hepatic decompensation
outcome after plate osteosynthesis of proximal humerus fractures using continous passive motioning therapy

Conditions: Proximal Humerus Fracture

Summary: patients suffering from a proximal humerus fracture treated with plate osteosynthesis will receive either regular aftercare (physiotherapy) or aftercare assisted with continous passive motion (physiotherapy + cpm). change in functional and patient-reported outcome (prom) over time will be evaluated and compared.

the investigators will conduct a prospective, monocentric study focusing on the rehabilitation process after surgical treatment of proximal humerus fractures. patients treated with plate osteosynthesis and eligible to participate will be randomly assigend to either a regular rehabilitation protocol (immobilization and physiotherapy) or a rehabilitation protocol with the additional use of a continous passive motion device (immobilization, physiotherapy and cpm). after 6 and 12 weeks as well as 1 year in a follow-up examination functional (range of motion) and patient-reported outcome (disabilities of arm, shoulder and hand score \[dash\], constant-score, pain on visual analogue scale, subjective satisfaction) will be evaluated. results will be compared towards possible differences and effect of cpm therapy. in addition demographic factors (age, sex, bmi, etc.) and complications will be analysed.

Eligibility criteria:
inclusion criteria: * patients with proximal humeral fracture treated with plate osteosynthesis during the enrollment period * understanding of german language (written and oral) * written informed consent of the patient or the legal guardian exclusion criteria: * patients not meeting the aforementioned criteria * patients with the need of / or an already existing endoprosthesis * patients with ipsilateral fracture of the distal radius * patients with cerebral damage (contusio or commotio cerebri) * patients with affection of the brachial plexus or nerve palsy * non-compliance

Keywords: proximal humerus fracture plate osteosynthesis rehabilitation continuous passive motion
the effect of respiratory training on exercise tolerance in copd

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: exercise intolerance is one of the key disabling factors in patients with chronic obstructive pulmonary disease (copd). although multifactorial, exercise intolerance involves physiological interactions between respiratory and locomotor muscles that may contribute to further reducing exercise tolerance in copd. the respiratory muscle work during exercise is closely related to breathing and could induce respiratory muscle fatigue in patients with copd. respiratory muscle training is an intervention strategy that is sometimes proposed for some patients with copd, especially whose with inspiratory muscle weakness. it was reported that inspiratory muscle training improves inspiratory muscle endurance and strength, dyspnea and exercise tolerance. there are two types of inspiratory muscle training, inspiratory muscle training against a resistive loading and normocapnic hyperpnoea. the advantage of normocapnic hyperpnoea compared to resistive training is the possibility to simulate the exercise ventilation level while maintaining stable the partial pressure of arterial carbon dioxide and end-tidal pressure of carbon dioxide and to solicit the inspiratory and expiratory muscles together, which could increase respiratory muscle tolerance and avoid their fatigue during whole-body exercise. therefore, the aim of this project is to study the effect of normocapnic hyperpnoea training on exercise tolerance in patients with copd. we hypothesize that greater improvement in cycling exercise tolerance will be observed following 6-weeks normocapnic hyperpnoea training compared to a sham intervention in patients with copd.


Eligibility criteria:
inclusion criteria: * age ≥ 40 years; * chronic airflow obstruction : fev1/fvc \< 0.7, fev1 of 30 to 80% predicted, after bronchodilation; exclusion criteria: * inability to perform a cycling exercise; * diagnosed of one of more comorbidities that may limit exercise tolerance : cardiovascular, metabolic, endocrine, gastrointestinal, renal, neurological or rheumatologically disease; * recent copd exacerbation (\< 3 months); * recent cancer; * a daily dose of prednisone \> 10 mg; * hypoxemia at rest or during exercise: pao2 \< 60 mmhg or spo2 ≤ 88%; * body mass index \> 30 kg/m²; * pregnancy; * skinfold at intercostal or vastus lateralis muscle \> 1.5 cm.

Keywords: respiratory training copd muscle oxygenation muscle fatigue oxygen kinetic exercise tolerance
chickpea pulao using fenugreek seeds and indian rennet for improving blood glycaemic levels

Conditions: Glucose Metabolism Disorders (Including Diabetes Mellitus)

Summary: the goal of this study was to perform a clinical trial to compare the impact of herbal chickpea pulao (cooked indian-pakistani rice dish) on improving postprandial blood glucose levels in type-2 diabetic people. the main questions it aims to answer are: * whether indian rennet and fenugreek seed extract can modulate blood sugar levels or not? * at what concentration the flavor, taste, and blood sugar impact were acceptable? participants were provided with control and intervention herbal chickpea pulao for a period of 21 days and asked to provide feedback on taste, flavor, and over-acceptability, and their postprandial blood glucose levels were checked.


Eligibility criteria:
inclusion criteria: * people having type-2 diabetes disease * must be able to consume chickpea rice pulao * must not be on vegan or keto diet exclusion criteria: * healthy people without diabetes * people with less than 18 years of age

Keywords: chickpea pulao fenugreek seeds indian rennet glucose modulating
study to assess the safety and impact on humoral sensitization of sanguinate in patients with end stage renal disease

Conditions: Renal Insufficiency, Chronic

Summary: a phase ib, open-label, single arm study to assess the safety, pharmacokinetics, and impact on humoral sensitization of sanguinate infusion in patients with end stage renal disease (esrd).

the purpose of the study is to investigate the safety of sanguinate on humoral sensitization in end stage renal disease (esrd) patients receiving dialysis.

Eligibility criteria:
inclusion criteria: 1. patient diagnosed with end state renal disease requiring renal replacement therapy. 2. age 18 - 65 years of age who are on maintenance hemodialysis for at least 3 months prior to the study start; 3. stable dialysis treatment regimen 3 times per week for ≥ 2 months prior to screening visit; 4. hemoglobin \>7.5 g/dl with or without clinical symptoms; 5. women of childbearing potential must have a negative serum pregnancy test and must use a reliable method of contraception during the study period; 6. signed and dated informed written consent by the subject or his/her legally authorized representative; exclusion criteria: 1. in the judgment of the investigator the patient is not a good candidate for the study; 2. blood transfusion with in the last 90 days from date of screening; 3. symptoms or electrocardiogram (ecg)-based signs of acute myocardial infarction, unstable angina pectoris, decompensated heart failure, third degree heart block or cardiac arrhythmia associated with hemodynamic instability; 4. total bilirubin greater than 1.5 mg/dl or transaminase (alt, ast) elevations greater than 2 times the upper limit of the laboratory reference range or evidence of significant hepatic insufficiency; 5. concurrent or prior treatment within 90 days of screening with an investigational medication; 6. chronic treatment (as determined by the investigator) with any immunosuppressive medication (including corticosteroids) within the past 90 days of screening; 7. evidence or history of regular alcohol abuse; 8. screening laboratory result(s) determined to be clinically significant by the investigator; 9. screening laboratory result indicating hiv-positivity, or previously diagnosed with aids, aids related complex or any other immunodeficiency; 10. screening laboratory result or laboratory results performed within one year indicating positivity for hepatitis b surface antigens, hepatitis b core antibodies, or hepatitis c antibodies; 11. uncontrolled diabetes mellitus (patients with hba1c \> 9% at screening)
different epidural initiation volumes

Conditions: Pain, Postoperative

Summary: the aim of this study is to compare the effect of different epidural initiation volumes on postoperative pain scores, local anesthetic requirements, and motor block in patients who undergo patient controlled epidural analgesia for postoperative pain after cesarean section.

90 minutes after combined epidural spinal catheter insertion, three different volumes (5 ml, 10 ml, and 20 ml) are administered with a patient-controlled epidural analgesia (pcea) device through the epidural catheter. for each group, 0.625% bupivacain + 2 μg/ml fentanyl, is administered. the visual analog scale, first analgesic demand time, the number of pcea requirement per hour, morphine requirement, nausea-vomiting, itching, motor block, hypotension, and total consumed analgesic, and ephedrine amounts of the patients are recorded in the recovery room and at postoperative 2, 4, 6, 12 hours.

Eligibility criteria:
inclusion criteria: * american society of anesthesiology risks classification ii * term pregnant exclusion criteria: * multiple pregnancy * diabetes mellitus * hypertension * coagulopathy * severe cardiac, neurological and pulmonary disease * allergy to the study drugs * difficulty in understanding the use of the patient controlled analgesia device

Keywords: cesarean section combined spinal epidural anesthesia patient controlled epidural analgesia postoperative pain
effects of instrument assisted soft tissue mobilization on healthy tissue regarding range of motion and grip strength

Conditions: Healthy

Summary: the goal of this clinical trial is to study the effects of instrument assisted soft tissue mobilization (iastm) in healthy adult volunteers. the main questions it aims to answer are: * does iastm treatment have an effect on range of motion (rom) as measured in the elbow, wrist and thumb? * does iastm treatment have an effect on grip strength? researchers will compare pre-test and post-test iastm treatment intervention data to the pre-test and post-test data of the no treatment control intervention to see if iastm works to change rom and/or grip strength. participants will: * complete a questionnaire on medical history and injury background * have elbow, wrist, and thumb range of motion (rom) measurements taken on both upper extremities using a goniometer * undergo grip strength testing using a jamar hand dynamometer in three positions on both upper extremities * be randomly assigned to either iastm first treatment group or the wait/control first group * receive iastm treatment techniques including application of emollient to the skin to reduce friction on the surface followed by scanning the forearm wrist flexors and wrist extensors and the biceps and triceps using the hg8-scanner tool and then the concave tool corresponding to the size of the structure being treated will be used (hg6-large multi-curve, hg5-medium multi-curve, hg4-small multi-curve) in each direction for a total treatment time of 20 minutes for both upper extremities in all listed areas. * simply wait for 20 minutes (the duration of time treatment with iastm would require) when assigned to the control group. * complete elbow, wrist and thumb range of motion and grip strength measurement testing at the end of the first session. * return within fourteen days after the first session in order to undergo the opposite experience (iastm first means wait/control second and vice versa). * undergo the same baseline pre-test measurements for range of motion and grip strength as the first session. * experience the opposite treatment group for the same time period as the first session. * undergo the post-test range of motion and grip strength testing at the end of the second session for data comparison.

no further information to note than what is described in the summary or elsewhere

Eligibility criteria:
inclusion criteria: * a volunteer from a small regional university student body, faculty or staff may participate. exclusion criteria: * acute spinal cord injury with neurological deficits * neurological disorders * acute upper extremity injury such as sprain or strain * any type of upper extremity fracture within the past 12 months * cervical disc pathology with radicular symptoms * use of blood thinning or clotting medications * known connective tissue disorder

Keywords: instrument assisted soft tissue mobilization range of motion grip strength
musculoskeletal measurements in transfemoral amputees

Conditions: Lower Limb Loss

Summary: the aim of this study was to identify posture asymmetries in transfemoral amputees utilizing clinical evaluation measures. the purposes of this investigation were: 1) to measure the limb length indirectly to determine the proportion of participants with lld and to quantify the mean amount of discrepancy. the investigators hypothesized that a majority of transfemoral amputees would present with a short prosthetic limb. 2) to measure pelvic tilt to determine if transfemoral amputees undergo musculoskeletal adaptations similar to those reported in the literature. the investigators hypothesized that transfemoral amputees would present with a greater degree of anterior pelvic tilt and pelvic innominate asymmetry than what has been previously reported. 3) to assess restriction in lateral trunk flexion and hip extension to determine if asymmetry was present and if it was related to the increase in anterior pelvic tilt. the investigators hypothesized that restrictions would be found in the lateral trunk flexors and hip flexors on the amputated side contributing to posture asymmetry at the pelvis. 4) to determine if musculoskeletal adaptations at the pelvis were affected by prosthetic limb length, lateral trunk flexion and hip extension restrictions, and residual limb length. the investigators hypothesized that the previously reported posture asymmetries would contribute to musculoskeletal adaptations at the pelvis and trunk. results of the present study will provide a reference for clinicians when using clinical evaluation measures to determine the presence of posture asymmetries in transfemoral amputees. if posture asymmetries are detected, clinicians need to determine musculoskeletal structures at fault and offer treatment solutions to prevent secondary impairments.


Eligibility criteria:
inclusion criteria: healthy individuals with: 1. unilateral transfemoral or knee disarticulation amputations between the ages 18 to 80. 2. history of at least one episode of low back pain in the past. 3. ambulate independently of an assisted device or those who require the use of a cane or crutches for walking on level grounds. 4. comfortably fitted with prosthesis for a period of at least 6 months. 5. more than 12 months post-amputation. exclusion criteria: individuals with: 1. amputation on the contralateral limb. 2. open wound on non-amputated side. 3. neurological disorders such as parkinson's disease or stroke that affect their ability to ambulate. 4. who require a walker or wheelchair for locomotion on level ground.

Keywords: amputation amputees artificial limbs leg length inequality lower extremity pelvis posture prostheses range of motion trunk muscles
quality of life outcomes in spinal cord stimulation

Conditions: Neuropathic Pain; Low Back Pain

Summary: the investigators will be evaluating quality of life outcomes in patients who are undergoing routine spinal cord stimulator implant for uncontrolled pain. patients will be evaluated pre and post-operatively for quality of life improvements, pain control, and functionality.

this is a prospective cohort study for patients who will be undergoing implantation of spinal cord stimulator for pain. all patient will have implantation done at university hospital newark or newark beth israel. the data points that will be collected will be the patient's weight, bmi, and detailed questionnaires regarding disability, activity, quality of life, and depression. the first data set will be taken pre-operatively at the doc, 90 bergen street, suite 8100. those patients enrolled will have the same data taken again upon subsequent postoperative visits at 3, 6, and 12 months. being that spinal cord stimulation is a well-documented safe procedure, the investigators do not anticipate any deviation from the standard risks of surgery. with that being said the primary safety endpoint would be if there is an increased complication rate, secondary to the procedure, greater than the current anticipated risk rate. this is a purely observational study. patients are not being recruited for an intervention but are being recruited during routine clinical practice.

Eligibility criteria:
inclusion criteria: * patients with neuropathic pain or axial back pain that is not controlled by oral analgesics, opioids, and has failed conservative management. * ages 18-90 with no ethnicity or gender predilections. exclusion criteria: * patients who have spinal cord injury, multiple stimulator revisions, drg stimulators, intrathecal pain pumps, complex regional pain syndrome, previous spinal cord stimulator implant, mechanical instability requiring fusion, myelopathy, psychological condition precluding them from complying with therapy, illegal drug abuse including heroin, cocaine, and illegally obtained prescription pills, or have previously been or are currently involved in litigation for medical malpractice.

Keywords: spinal cord stimulation
usefulness of non-invasive radiofrequency therapy for facial contouring

Conditions: Subcutaneous Fat

Summary: to evaluate the efficacy of novel noninvasive rf technology for reduction of submental fat.

recently, novel radiofrequency (rf) technology was introduced as a promising tool for non-invasive body and face contouring, which can heats subcutaneous fat up to 45℃ continuously without surface damage and induces adipocytes apoptosis. subjects with an excessive subcutaneous fat on the submental area received twice treatments at 1-month intervals. clinical outcomes including the thickness of the submental fat (measured by ultrasound) and the submental circumference (measured by a tape measure), and clinical photographs were obtained at baseline, and 1-month and 6-month after last treatment.

Eligibility criteria:
inclusion criteria: * clinically appreciable localized excess of subcutaneous fat on the submental area * no history of systemic underlying disease exclusion criteria: * any infectious or inflammatory skin diseases * keloids * psychiatric patients * systemic underlying disease * who had taken aesthetic procedure on the face, before 6-month * more than 5% weight change were dropped out.

Keywords: radiofrequency submental fat fat reduction body contouring
glutamine in preventing peripheral neuropathy in patients with multiple myeloma receiving bortezomib

Conditions: Chemotherapeutic Agent Toxicity; Multiple Myeloma; Peripheral Neuropathy

Summary: this randomized phase ii trial studies glutamine in preventing peripheral neuropathy in patients with multiple myeloma who are receiving bortezomib. glutamine may help prevent peripheral neuropathy in patients receiving chemotherapy

primary objectives: i. estimate the objective effect size of glutamine compared to placebo as a prophylactic intervention to prevent bortezomib-induced peripheral neuropathy in multiple myeloma patients 4 months after their first dose of study drug. secondary objectives: i. estimate whether glutamine delays or prevents the onset or worsening of any neuropathy as determined by national cancer institute (nci)-common terminology criteria for adverse events (ctcae) v4.03 criteria. ii. determine if glutamine may improve adherence to bortezomib therapy. iii. assess response rate (rr) and clinical benefit response rate (cbr) according to uniform international response criteria and modified european group for blood and marrow transplantation (ebmt) criteria. iv. determine if glutamine may improve quality of life (qol) at 4 months. outline: patients are randomized to 1 of 2 treatment arms. arm i: patients receive glutamine orally (po) twice daily (bid). courses repeat every 28 days for 4 months in the absence of disease progression or unacceptable toxicity. arm ii: patients receive placebo po bid. courses repeat every 28 days for 4 months in the absence of disease progression or unacceptable toxicity.

Eligibility criteria:
inclusion criteria: * patients with a diagnosis of multiple myeloma who received bortezomib at a dose of 1.3mg/m2 sq weekly * no evidence of severe pre-existing peripheral neuropathy, nci-ctcae v4.03 =\< 2 * performance status =\< 2 on the eastern cooperative oncology group (ecog) performance scale exclusion criteria: * concurrent use of thalidomide, vincristine, platinum compound, or other agent known to cause significant neuropathy (concurrent lenalidomide will be allowed) * hospitalization with clinical evidence of active infections as manifested by recurrent fevers, positive blood culture results, or requiring intravenous antibiotic therapy * inadequate liver and renal function with liver transaminases 3x the upper limit of normal * glomerular filtration rate (gfr) according to cockcroft-gault \< 30 ml/min * uncontrolled congestive heart failure * uncontrolled mood disorders * fasting blood glucose \>150mg/dl or blood sugar (non-fasting) \>200mg/dl if no history of diabetes. uncontrolled diabetes with hga1c greater 7% with last evaluation. * seizure disorder * monosodium glutamate (msg) allergy or soy allergy * life expectancy of shorter than 3 months based on clinical laboratory parameters and the investigator's opinion * uncorrected vitamin b12 or folate deficiency on last evaluation. * use of over the counter (otc) supplements other than one multivitamin tablet a day * women who are pregnant or breastfeeding